Targeted therapies only work when inhibiting the target pathway disrupts the oncogenic process. Celcuity’s platform provides unparalleled insights into oncogenic pathways by analyzing live patient tumor cells. We harness these insights to develop new targeted therapies for cancer patients.
Location: United States, Minnesota, Minneapolis
Founded date: 2012
Investors 1
| Date | Name | Website |
| - | Gravity Fu... | gravityfun... |
Mentions in press and media 14
| Date | Title | Description |
| 14.08.2024 | Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update | Announced plan to initiate Phase 3 VIKTORIA-2 trial evaluating gedatolisib combined with fulvestrant plus a CDK4/6 inhibitor as first-line treatment for patients with HR+, HER2- advanced breast cancer; expect to enroll first patient in Q2 2... |
| 06.03.2024 | Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024 | - |
| 07.11.2023 | Cancer research company Celcuity raises $50 million | - |
| 08.05.2023 | Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call | MINNEAPOLIS, MN / ACCESSWIRE / May 8, 2023 / Celcuity Inc. CELC, a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it will release its financial results for the first quar... |
| 18.04.2023 | Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023 | Gedatolisib demonstrated superior anti-proliferative potency and efficacy in endometrial, ovarian and cervical cancer cell lines compared to other PAM inhibitors evaluated regardless of PTEN, P13K, or AKT mutational status MINNEAPOLIS, MN /... |
| 16.03.2023 | Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023 | MINNEAPOLIS, MN / ACCESSWIRE / March 15, 2023 / Celcuity Inc. CELC, a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced publication of an abstract reporting data from preclinical... |
| 09.12.2022 | Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium | High response rates and encouraging median progression free survival rates were observed in patients regardless of PIK3CA mutation status Median progression free survival (PFS) of 42.3 months was reported for patients who were treatment naï... |
| 09.05.2022 | Celcuity Inc. Schedules Release of First Quarter 2022 Financial Results and Webcast/Conference Call | MINNEAPOLIS, MN / ACCESSWIRE / May 9, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that it... |
| 05.04.2022 | Celcuity to Participate in Upcoming Needham and Canaccord Genuity Investor Conferences | MINNEAPOLIS, MN / ACCESSWIRE / April 5, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that ... |
| 23.03.2022 | Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolisib in the Treatment of Advanced Breast Cancer, and Business Updates | Finalized pivotal Phase 3 trial design following formal meetings with FDA Received FDA Fast Track designation for gedatolisib in HR+/HER2- metastatic breast cancer Presented updated Phase 1b data during a Spotlight Poster-Discussion Session... |
Show more